Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 286

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 286
---
 from April 2017 until April 2024, he served at the Assaf Harofeh Medical Center. On April 2017 until April 2021, he served as a Professor at Assaf Harofeh Medical Center. He began his medical career in August 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May 2017. Professor Revel received his PhD from Tel -AvivUniversity and an MD degree from the Hebrew University of Jerusalem, Israel. Dr. Eric Konofal, MD, Ph.D., Head of DOXA program Dr. Eric Konofal has served as NLS’s Chief Scientific Officer since February 2021 and as its Interim Chief Medical Officer since January 2024. Dr. Konofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 30 years in the field of sleep research, including narcolepsy and hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal has served as a Senior Medical Consultant for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debré Hospital (APHP). Dr. Konofal received his MD and PhD from University Pierre -MarieCurie in Paris, France. To approve this Proposal11, a resolution passed by a Simple Majority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 11. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 11. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 11. 122 Approval of THE Compensation for the Members of the NLS Board and Executive Management (PROPOSALs 12.1 – 12.2) Pursuant to the Swiss Code of Obligations, the shareholders’ meeting is required to vote on the remuneration that the board of directors, the executive board and the board of advisors directly or indirectly receive from the company. The Articles outline the specifics of this vote and may also stipulate the procedure to follow if the shareholders’ meeting does not approve the proposed remuneration. In accordance with the Articles, the shareholders’ meeting must approve the proposals of the board of directors in relation to: